wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEF
Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEF
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
P2860
Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEF
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37690136-191F142B-70AB-41D1-99DB-05D6EE8F9EEF
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
61df8f351ecaf64f0d7b5824bc166c714de467b2
P2860
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.